JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
Status:
ENROLLING_BY_INVITATION
Trial end date:
2029-07-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, single-arm phase Ib clinical trial. The aim of this study is to assess the safety and efficacy of JS014 in combination with Toripalimab and transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). The primary endpoint is the safety and tolerability, while the secondary endpoints include objective response rate (ORR), disease control rate (DCR), time to progression (TPP), progression-free survival (PFS), and overall survival (OS).